Thomas Stankovich, Chief Financial Officer at ReShape Lifesciences Inc. (RSLS), sold 172 shares at $0.25 ($39) on 2023-12-31, disclosed to the SEC on 2024-08-13.
Tax-driven sale ($39) by Chief Financial Officer — typically RSU/option vesting with shares sold to cover withholding tax. Not a directional view.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.23 | 39 | $9 | 23.1% |
| 2 | $0.25 | 42 | $11 | 27.1% |
| 3 | $0.17 | 43 | $7 | 18.8% |
| 4 | $0.25 | 48 | $12 | 30.9% |
| Total | $0.23 avg | 172 | $39 | 100% |
| Filing → |
| RSLS | SELL | 2023-07-06 | $746 | — | Filing → |
| RSLS | BUY | 2023-07-06 | $27K | — | Filing → |
| RSLS | SELL | 2023-03-07 | $4K | — | Filing → |